{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:15Z","timestamp":1789587015749,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.peptides.2024.171203","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T15:35:15Z","timestamp":1712244915000},"page":"171203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy"],"prefix":"10.1016","volume":"177","author":[{"given":"Xiao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingzhuang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2024.171203_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13679-015-0169-4","article-title":"Overweight and obesity: prevalence, consequences, and causes of a growing public health problem","volume":"4","author":"Williams","year":"2015","journal-title":"Curr. Obes. Rep."},{"issue":"11","key":"10.1016\/j.peptides.2024.171203_bib2","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Pich\u00e9","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.peptides.2024.171203_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105782","article-title":"Anti-diabetic drugs and weight loss in patients with type 2 diabetes","volume":"171","author":"Lazzaroni","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.peptides.2024.171203_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-8587(20)30022-X","article-title":"Inadequate \u03b2-cell mass is essential for the pathogenesis of type 2 diabetes","volume":"8","author":"Weir","year":"2020","journal-title":"Lancet Diabetes Endo"},{"key":"10.1016\/j.peptides.2024.171203_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154838","article-title":"Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes","volume":"123","author":"Yun","year":"2021","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.peptides.2024.171203_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13349","article-title":"The dietary inflammatory index, obesity, type 2 diabetes, and cardiovascular risk factors and diseases","volume":"23","author":"Hariharan","year":"2022","journal-title":"Obes. Rev."},{"issue":"1","key":"10.1016\/j.peptides.2024.171203_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","article-title":"Guideline recommendations and the positioning of newer drugs in type 2 diabetes care","volume":"9","author":"Marx","year":"2021","journal-title":"Lancet Diabetes Endo"},{"issue":"3","key":"10.1016\/j.peptides.2024.171203_bib8","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1530\/EC-21-0025","article-title":"Cholecystokinin and the hormone concept","volume":"10","author":"Rehfeld","year":"2021","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.peptides.2024.171203_bib9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"issue":"6","key":"10.1016\/j.peptides.2024.171203_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.nut.2012.11.015","article-title":"Nutrients related to GLP1 secretory responses","volume":"29","author":"Mansour","year":"2013","journal-title":"Nutrition"},{"issue":"12","key":"10.1016\/j.peptides.2024.171203_bib11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.peptides.2024.171203_bib12","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2024.171203_bib13","first-page":"171","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"Volume 4","author":"Maselli","year":"2021","journal-title":"Diabetes.: Res. Clin. Pract."},{"issue":"9","key":"10.1016\/j.peptides.2024.171203_bib14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/13543776.2023.2274905","article-title":"An updated patent review of GLP-1 receptor agonists (2020-present)","volume":"33","author":"Lu","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"issue":"3","key":"10.1016\/j.peptides.2024.171203_bib15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.jmedchem.9b00835","article-title":"Recent developments in therapeutic peptides for the glucagon-like peptide 1 and 2 receptors","volume":"63","author":"Suzuki","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2024.171203_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.peptides.2024.171203_bib17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/dom.13564","article-title":"Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK","volume":"21","author":"Viljoen","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.peptides.2024.171203_bib18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"15","key":"10.1016\/j.peptides.2024.171203_bib19","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J. Med. Chem."},{"issue":"10317","key":"10.1016\/j.peptides.2024.171203_bib20","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"issue":"10403","key":"10.1016\/j.peptides.2024.171203_bib21","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2024.171203_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.170939","article-title":"An update on peptide-based therapies for type 2 diabetes and obesity","volume":"161","author":"Bailey","year":"2023","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.peptides.2024.171203_bib23","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1038\/s41598-019-44591-8","article-title":"Combined Amylin\/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss","volume":"9","author":"Liberini","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.peptides.2024.171203_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1476-5381.2011.01537.x","article-title":"GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities","volume":"166","author":"Roth","year":"2012","journal-title":"Brit. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.peptides.2024.171203_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/acs.jmedchem.3c01049","article-title":"Discovery of a novel glucagon-like peptide-1 (GLP-1) analogue from bullfrog and investigation of its potential for designing GLP-1-based multiagonists","volume":"67","author":"Jiang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.peptides.2024.171203_bib26","doi-asserted-by":"crossref","first-page":"14201","DOI":"10.1021\/acs.jmedchem.2c01385","article-title":"Design of Xenopus GLP-1-based long-acting dual GLP-1\/Y2 receptor agonists","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.peptides.2024.171203_bib27","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2337\/db21-0848","article-title":"GIPR agonism inhibits PYY-induced nausea-like behavior","volume":"71","author":"Samms","year":"2022","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.peptides.2024.171203_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/lt.23782","article-title":"Automated image analysis method for detecting and quantifying macrovesicular steatosis in hematoxylin and eosin\u2013stained histology images of human livers","volume":"20","author":"Nativ","year":"2014","journal-title":"Liver Transpl."},{"key":"10.1016\/j.peptides.2024.171203_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"issue":"9","key":"10.1016\/j.peptides.2024.171203_bib30","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.peptides.2024.171203_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264974","article-title":"Preclinical evaluation of a protracted GLP-1\/glucagon receptor co-agonist: translational difficulties and pitfalls","volume":"17","author":"Simonsen","year":"2022","journal-title":"Plos One"},{"key":"10.1016\/j.peptides.2024.171203_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2024.171203_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101533","article-title":"Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice","volume":"63","author":"Knerr","year":"2022","journal-title":"Mol. Metab."},{"issue":"18","key":"10.1016\/j.peptides.2024.171203_bib34","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2024.171203_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejps.2018.07.032","article-title":"Lipidation and conformational constraining for prolonging the effects of peptides: Xenopus glucagon-like peptide 1 analogues with potent and long-acting hypoglycemic activity","volume":"123","author":"Han","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.peptides.2024.171203_bib36","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","article-title":"The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide","volume":"62","author":"Kanoski","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.peptides.2024.171203_bib37","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55164","article-title":"The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling","volume":"9","author":"Worth","year":"2020","journal-title":"eLife"},{"issue":"Supplement_1","key":"10.1016\/j.peptides.2024.171203_bib38","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab048.108","article-title":"Preclinical weight loss efficacy of AM833 in combination with semaglutide in rodent models of obesity","volume":"5","author":"John","year":"2021","journal-title":"J. Endocr. Soc."},{"issue":"10","key":"10.1016\/j.peptides.2024.171203_bib39","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/13543776.2020.1811851","article-title":"GLP-1R agonists for the treatment of obesity: a patent review (2015-present)","volume":"30","author":"Liu","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.peptides.2024.171203_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.peptides.2018.10.013","article-title":"Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy","volume":"110","author":"Graham","year":"2018","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.peptides.2024.171203_bib41","article-title":"Combined GLP-1 receptor agonist and amylin analogue pharmacotherapy to treat obesity comorbid with type 1 diabetes","volume":"1","author":"Wong","year":"2023","journal-title":"JCEM Case Rep."},{"key":"10.1016\/j.peptides.2024.171203_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175397","article-title":"Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin","volume":"938","author":"Melander","year":"2023","journal-title":"Eur. J. Pharmacol."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978124000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978124000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:35:37Z","timestamp":1717115737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978124000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":42,"alternative-id":["S0196978124000561"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2024.171203","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2024.171203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"171203"}}